Whitehawk Therapeutics (WHWK) Leases (2019 - 2024)
Whitehawk Therapeutics (WHWK) has disclosed Leases for 6 consecutive years, with $787000.0 as the latest value for Q4 2024.
- On a quarterly basis, Leases fell 32.68% to $787000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $787000.0, a 32.68% decrease, with the full-year FY2024 number at $787000.0, down 32.68% from a year prior.
- Leases was $787000.0 for Q4 2024 at Whitehawk Therapeutics, down from $886000.0 in the prior quarter.
- In the past five years, Leases ranged from a high of $1.7 million in Q2 2022 to a low of $9452.0 in Q2 2021.
- A 5-year average of $829310.9 and a median of $886000.0 in 2024 define the central range for Leases.
- Peak YoY movement for Leases: crashed 91.76% in 2021, then surged 17388.36% in 2022.
- Whitehawk Therapeutics' Leases stood at $89761.0 in 2020, then soared by 520.54% to $557000.0 in 2021, then skyrocketed by 173.25% to $1.5 million in 2022, then dropped by 23.19% to $1.2 million in 2023, then crashed by 32.68% to $787000.0 in 2024.
- Per Business Quant, the three most recent readings for WHWK's Leases are $787000.0 (Q4 2024), $886000.0 (Q3 2024), and $982000.0 (Q2 2024).